Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.
Schouten AEM, Hiensch AE, Frederix GWJ, Monninkhof EM, Schmidt ME, Clauss D, Gunasekara N, Belloso J, Trevaskis M, Rundqvist H, Wiskemann J, Müller J, Sweegers MG, Fremd C, Altena R, Bijlsma RM, Sonke G, Lahuerta A, Mann GB, Francis PA, Richardson G, Malter W, Kufel-Grabowska J, van der Wall E, Aaronson NK, Senkus E, Urruticoechea A, Zopf EM, Bloch W, Stuiver MM, Wengstrom Y, Steindorf K, van der Meulen MP, May AM. Schouten AEM, et al. Among authors: fremd c. J Clin Oncol. 2025 Jan 13:JCO2401441. doi: 10.1200/JCO-24-01441. Online ahead of print. J Clin Oncol. 2025. PMID: 39805062
Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial.
Hiensch AE, Depenbusch J, Schmidt ME, Monninkhof EM, Pelaez M, Clauss D, Gunasekara N, Zimmer P, Belloso J, Trevaskis M, Rundqvist H, Wiskemann J, Müller J, Sweegers MG, Fremd C, Altena R, Gorecki M, Bijlsma R, van Leeuwen-Snoeks L, Ten Bokkel Huinink D, Sonke G, Lahuerta A, Mann GB, Francis PA, Richardson G, Malter W, van der Wall E, Aaronson NK, Senkus E, Urruticoechea A, Zopf EM, Bloch W, Stuiver MM, Wengstrom Y, Steindorf K, May AM. Hiensch AE, et al. Among authors: fremd c. Nat Med. 2024 Oct;30(10):2957-2966. doi: 10.1038/s41591-024-03143-y. Epub 2024 Jul 25. Nat Med. 2024. PMID: 39054374 Free PMC article. Clinical Trial.
Palliative Radiotherapy for Symptomatic Locally Advanced Breast Cancer.
Hoeltgen L, Meixner E, Hoegen P, Sandrini E, Weykamp F, Forster T, Vinsensia M, Lang K, König L, Arians N, Fremd C, Michel LL, Smetanay K, Schneeweiss A, Wallwiener M, Debus J, Hörner-Rieber J. Hoeltgen L, et al. Among authors: fremd c. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231164537. doi: 10.1177/15330338231164537. Technol Cancer Res Treat. 2023. PMID: 37038619 Free PMC article.
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy.
Pixberg C, Zapatka M, Hlevnjak M, Benedetto S, Suppelna JP, Heil J, Smetanay K, Michel L, Fremd C, Körber V, Rübsam M, Buschhorn L, Heublein S, Schäfgen B, Golatta M, Gomez C, von Au A, Wallwiener M, Wolf S, Dikow N, Schaaf C, Gutjahr E, Allgäuer M, Stenzinger A, Pfütze K, Kirsten R, Hübschmann D, Sinn HP, Jäger D, Trumpp A, Schlenk R, Höfer T, Thewes V, Schneeweiss A, Lichter P. Pixberg C, et al. Among authors: fremd c. ESMO Open. 2022 Dec;7(6):100637. doi: 10.1016/j.esmoop.2022.100637. Epub 2022 Nov 21. ESMO Open. 2022. PMID: 36423362 Free PMC article. Clinical Trial.
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Fischer S, Götze TO, Omlin A, Baird RD, Dawson KM, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. Fischer S, et al. Among authors: fremd c. JCO Precis Oncol. 2022 Nov;6:e2200006. doi: 10.1200/PO.22.00006. JCO Precis Oncol. 2022. PMID: 36331248 Free PMC article. No abstract available.
Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer.
Meixner E, Hoeltgen L, Hoegen P, König L, Arians N, Michel LL, Smetanay K, Fremd C, Schneeweiss A, Debus J, Hörner-Rieber J. Meixner E, et al. Among authors: fremd c. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221118188. doi: 10.1177/15330338221118188. Technol Cancer Res Treat. 2022. PMID: 35950239 Free PMC article.
28 results